Batroxobin, a thrombin-like enzyme from Bothrops atrox moojeni venom, is associated with the reduction of fibrinogen levels in plasma and the enhancement of anticoagulation and fibrinolysis. In this study, 15 patients with deep vein thrombosis (DVT) achieved successful limb salvage after the administration of batroxobin. We found that the levels of CD34þ, CD31þ, CD34þ/CD31þ, and vascular endothelial cadherin (VE-cadherinþ) cells had increased in the peripheral blood of patients at 7 days and 14 days after treatment. At 0 day, 7 days, and 14 days, the percentages of CD34þ cells, which are assumed to be hematopoietic stem cells, are 0.39% + 0.43%, 0.71% + 0.50%, and 1.11% + 0.66%, respectively. The levels of CD34þ cells at 14 days are significantly higher than the levels on the first day (P ¼ .004). The levels of CD31þ cells and VE-cadherinþ cells, which represent mature endothelial cells, at 7 days (34.15% + 11.32%, P ¼ .013; 1.25% + 1.39%, P ¼ .014) and 14 days (35.21% + 7.66%, P ¼ .071; 1.85% + 2.60%, P ¼ .117) were slightly elevated compared with those at 0 day (27.55% + 8.65%; 0.25 + 0.39%). The double positive of CD34 and CD31 cells are assumed to be endothelial progenitor cells (EPCs). The levels of CD34þ/CD31þ cells at 7 days (0.69% + 0.50%, P ¼ .001) and 14 days (1.07% + 0.66%, P ¼ .006) are significantly higher than that on the initial day (0.28% + 0.30%). The number of CD34þ/CD31þ cells significantly increased, indicating that in addition to its role in anticoagulation and fibrinolysis, treatment with batroxobin might simultaneously activate circulating EPCs that might promote the recanalization of the damaged vessel wall.
Introduction
Several defibrases with the potential for cleaving circulating fibrinogen have been extracted from viper venoms, of which ancrod (Arvin) has been extensively investigated in treating several clinical conditions. In Canada and Europe, ancrod was used for the treatment of vascular disorders, such as deep vein thrombosis (DVT), peripheral vascular diseases, retinal ischemia, and heparin-induced thrombocytopenia. 1 Similar to ancrod, batroxobin is also a thrombin-like enzyme derived from Bothrops atrox moojeni snake venom. It contains 231 amino acids and 12 cysteine residues, which are involved in 6 disulfide bonds. 2 Batroxobin is known to have defibrinogenating properties such as the ability to reduce fibrinogen levels in plasma and to enhance anticoagulation and fibrinolytic activities. The enzyme is currently being used clinically outside the United States for the treatment of various thrombotic diseases, including DVT, myocardial infarction, pulmonary embolism, and acute ischemic stroke. 3, 4 Deep vein thrombosis of lower limbs is a serious and potentially fatal disorder. The clinically important problems associated with venous thrombosis are death from pulmonary embolism, morbidity resulting from the acute event, recurrent venous thromboembolic events, and the post-thrombotic syndrome. 5 In this study, 15 patients with DVT achieved successful limb salvage after the administration of batroxobin, and fibrinogen levels are significantly reduced in plasma and remain low with repeated administrations. Furthermore, the number of CD34þ/CD31þ cells significantly increased after treatment, indicating that in addition to its role of enhancing anticoagulation and fibrinolysis, treatment with batroxobin might simultaneously activate circulating endothelial progenitor cells (EPCs) of bone marrow origin, which would facilitate the recanalization of the damaged vessel wall.
Patients, Materials, and Methods
Fifteen patients (mean age: 64 years; range: 37-80 years; 11 males, 4 females) with DVT were included in this study that was approved by the local ethical committee of the institution. After obtaining written informed consent, patients received batroxobin a first dose of 10 BU and then 5 BU by continuous intravenous infusion everyday for 14 days. Blood samples were obtained before batroxobin infusion and 7 and 14 days after starting the infusion. Following batroxobin, anticoagulation regimen includes subcutaneous injection of low-molecularweight heparin for 10 days (1 mg/kg, once every 12 hours [q12h]) and oral enteric-coated aspirin (100 mg) every day.
The plasma clotting times, including activated partial thromboplastin time (aPTT), prothrombin time (PT), thrombin time (TT), and fibrinogen concentration, were measured as described previously. 6 Venographic analysis for the recanalization of the blocked vein was performed on patients 1 day before and 2 weeks after treatment.
Before batroxobin infusion and 7 and 14 days after starting the infusion with informed consent, 10 to 15 mL of peripheral blood was obtained from patients. Mononuclear cells were isolated from peripheral blood using Ficoll-Hypaque (density, 1.077; Union Stemcell & Gene Engineering Company, Tianjin, China) density centrifugation. After 2 cycles of plastic adherence for 60 minutes, the cells were washed and suspended in phosphate-buffered saline (PBS, pH 7.4) containing 0.1% bovine serum albumin (BSA). Preparations of 2 Â 10 5 mononuclear cells isolated from peripheral blood and were phenotyped for PerCP-CD45, PE-CD34, FITC-CD31, and allophycocyanin (APC)-VE-cadherin. The labeled cells were resuspended after washing and analyzed within 2 hours using a FACScan flow cytometer (Becton-Dickinson, Franklin Lakes, NJ), as previously described. 7 Comparisons of the data of patients were done using the paired-samples t test, the level of significance being set at .05.
Result
All patients achieved successful limb salvage. Signs and symptoms of DVT including pain, calf swelling and/or erythema in the lower extremities disappeared, and all patients were monitored for 1 to 3 months after the initial treatment and none of the patients showed any recurrence of DVT. There was no subsequent death, no de novo diagnosis of cancer, no episode of symptomatic pulmonary embolism, and no complications associated with the anticoagulation therapy during the observation period.
Angiographic analyses for veins were carried out in 15 patients; almost all veins blocked achieved successful salvage after the administration of batroxobin for 14 days. Figure 1 shows representative venous angiography. Fibrinogen levels significantly decreased 7 and 14 days after treatment (Table 1) .
Mononuclear peripheral blood cells were obtained before batroxobin infusion and 7 and 14 days after starting the infusion. CD34, CD31, and VE-cadherin were measured by flow cytometry to determine the number of hematopoietic stem cells, endothelial cells, and EPCs. Table 2 shows the percentages of CD34þ, CD31þ, CD34þ/CD31þ, and VE-cadherinþ cells in the peripheral blood of patients at 0, 7, and 14 days after infusion of batroxobin. At 0 day, 7 days, and 14 days, the percentages of CD34þ cells, which are assumed to be hematopoietic stem cells, are 0.39% + 0.43%, 0.71% + 0.50%, and 1.11% + 0.66%, respectively. The levels of CD34þ cells at 7 days and 14 days are significantly higher than the levels on the first day (P ¼ .001 and P ¼ .004). The levels of CD31þ cells, which represent mature endothelial cells, at 7 days (34.15% + 11.32%, P ¼ .013) and 14 days (35.21% + 7.66%, P ¼ .071) were slightly elevated compared with those at 0 day (27.55% + 8.65%). The double positive of CD34 and CD31 cells are assumed to be EPCs. The levels of CD34þ/ CD31þ cells at 7 days (0.69% + 0.50%, P ¼ .001) and 14 days (1.07% + 0.66%, P ¼ .006) are significantly higher than that on the initial day (0.28% + 0.30%). Vascular endothelial cadherin is also a marker for EPCs. The percentage of VE-cadherinþ cells at 7 days (1.25% + 1.39%, P ¼ .014) is significantly higher than that at 0 day (0.25% + 0.39%). The percentage of VE-cadherinþ cells at 14 days is 1.85% + 2.60%, which is higher than that at 7 days. However, because blood samples from only 10 patients were measured at 14 days, no statistical difference were found compared with that at 0 days.
Discussion
The pathophysiology of vein thrombosis was postulated to by Virchow involving 3 interrelating factors: damage to the vessel wall, a stasis in blood flow, and the increase in blood coagulability. 5 Treatment options in DVT include anticoagulation, caval filters, fibrinolytic therapy, and surgical thrombectomy. However, about a third of patients with an initial episode of DVT have recurrence during the following year.
Research over the past few years has established that bone marrow-derived EPCs participate in local neovessel formation in the adult and vasculogenesis by EPCs may be an essential trigger for tissue and organ regeneration following pathological change in various critical stage diseases. [8] [9] [10] [11] [12] [13] [14] Transplantation of bone marrow-derived EPCs has been confirmed recently to be an effective way to cure vascular diseases. 15, 16 Endothelial progenitor cells are involved in many healing processes in cardiovascular diseases and can be found in spontaneously resolving venous thrombi. Santo et al 17 investigated whether the therapeutic administration of EPC might enhance the resolution of venous thrombi. Culture-expanded EPCs derived from human peripheral blood mononuclear cells (PBMNCs) were injected intravenously 2 and 4 days after thrombus induction in athymic nude rats. Recanalization of the inferior vena cava (IVC) and thrombus organization were assessed by laser Doppler measurements of the blood flow and immunohistochemical detection of endothelialized luminal structures in the thrombus of athymic nude rats. Endothelial progenitor cell transplantation resulted in significantly enhanced thrombus neovascularization and was accompanied by a substantial increase in intrathrombus blood flow. The results suggested that EPC transplantation might be of clinical value to facilitate venous thrombus resolution in cases where current therapeutic options have limited success. 17 In our previous study, we studied comparatively the effects of granulocyte colony-stimulating factor (G-CSF)-mobilized PBMNCs and CD34-depleted G-CSF-mobilized PBMNCs in an ischemia model of athymic nude mice. Granulocyte colonystimulating factor-mobilized PBMNCs promote vascular growth not only by incorporating into vessel walls but also by supplying angiogenic factors. The depletion of CD34þ cells attenuated the therapeutic efficiency of G-CSF-mobilized PBMNCs in response to ischemia-induced neovascularization. 18 In our clinical trial, results showed that autologous transplantation of either M-PBMNC or BM-MNC significantly promotes the improvement of limb ischemia in patients with lower limb arteriosclerosis obliterans. 19 In the current study, we found that CD34þ, CD31þ, CD34þ/CD31þ, and VE-cadherinþ cells showed various degrees of increase in the peripheral blood of patients at 7 days and 14 days after infusion with batroxobin. The number of CD34þ/CD31þ cells significantly increased after treatment (Figure 2 ), indicating that in addition to its role of enhancing anticoagulation and fibrinolysis, treatment with batroxobin might simultaneously activate circulating EPCs of bone marrow origin, which would facilitate the recanalization of the damaged vessel wall. Fibrinolysis would decrease blood coagulability and accelerate local blood flow. Therefore, with the treatment of batroxobin, EPCs could be mobilized to promote vessel wall rebuilding; the 3 mentioned interrelated factors of DVT would be ameliorated simultaneously.
In the current study, all patients achieved successful limb salvage after the administration of batroxobin, and fibrinogen levels significantly reduced in plasma and remained low with repeated administrations. This effect with the treatment of batroxobin could be explained by the above mechanism. The EPC mobilizing effect might be a consequence of its defibrinogenating activities. Wang et al 20 found that the plasma fibrinogen significantly influences vascular smooth muscle cells migration and that the inhibitory effect of the plasma of batroxobin-treated rats on vascular smooth muscle cells migration is related to the defibrinogenating action of batroxobin in vivo. However, whether the EPC mobilizing effect is directly induced by batroxobin or as a consequence of its defibrinogenating activities is unclear at this point and needs further study. 
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The precentage of CD34+/CD31+ cells in peripheral blood 0 day 7 days 14 days P = .001 P = .006 Figure 2 . The percentage of CD34þ/CD31þ cells in mononuclear cells of peripheral blood was measured before batroxobin infusion and 7 and 14 days after starting the infusion.
